News >

Future of MCL Treatment May Lie in Combinations, CAR T-Cell Therapy

Angelica Welch
Published: Wednesday, Nov 14, 2018

Robert Dean, MD

Robert Dean, MD

Experts are hard-pressed to find impactful, long-lasting treatment regimens for patients with mantle cell lymphoma (MCL). Moreover, Robert Dean, MD, said that BTK inhibitors and chimeric antigen receptor (CAR) T-cell therapy may address the unmet needs of the difficult-to-treat patient population.

State of the Science Summit™ on Hematologic Malignancies, Dean, a staff physician at Cleveland Clinic, discussed the promise for new therapies in MCL.

OncLive: Could you discuss the current treatment landscape of MCL?

Dean: The treatment of [patients with] MCL has evolved in a step-wise manner over the past 20 years. Studies have gradually incorporated the monoclonal antibody rituximab (Rituxan) into frontline therapy. Our approaches to frontline therapy have diverged into a more intensive route that is more appropriate for younger, fit patents who receive combination chemotherapy, followed by consolidation with high-dose chemotherapy and autologous stem cell transplant (ASCT). Now, rituximab maintenance follows that course of treatment.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication